In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
In order to perform relevant in vivo pharmacological investigations in drug discovery within dermatology it is fundamental to master or have access to relevant skin disease models that makes it possible to identify and validate targets and to screen and discover drugs in vivo. There is a strong need for highly predictive in vivo models in order to introduce the right drug candidates into the clinical phases of development. Recent advances in dermatological in vivo pharmacological disease models for psoriasis and atopic dermatitis are reviewed together with a discussion of the rationale for their application in drug discovery.
Petersen
Thomas K
TK
Department of Pharmacology, LEO Pharma, Denmark. thomas.petersen@leo-pharma.com
D000818:Animals; D030801:Animals, Genetically Modified; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends